The United Kingdom and the United States have finalized a key bilateral deal that will maintain no tariffs on British pharmaceutical shipments entering the US market.
The Terms of the Pact
As part of the deal, the UK has agreed to raise expenditure on drugs through the public health system. This commitment ensures that duties on these vital exports will be held at zero for a timeframe of the next three years.
This development is in response to previous statements to hike duties on patented pharmaceutical imports, with figures floated as high as double the cost.
"This deal between the Britain reinforces the worldwide climate for innovative medicines and establishes much-needed fairness to transatlantic pharmaceutical trade," an announcement noted.
Commercial Importance
Pharmaceuticals constitute one of the the United Kingdom's largest exports to the US, which is clearly the largest destination for major companies like GSK and AstraZeneca.
Statistics indicate that in the 12 months prior to last September, the UK shipped drugs worth over eleven billion pounds to the US. This value accounted for 17.4% of British export trade in that span.
"This guarantee secures work, stimulates capital expenditure and sets the stage for the UK to emerge as a global hub for medical research," a minister remarked.
Key UK Commitments
The pact entails several notable pledges from the UK:
- Higher Cost Ceiling: The UK will lift the price threshold at which it considers new treatments to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a target to increase total NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The sum drug companies must return to the NHS to stay within budget will be limited at 15%. Previously, refunds were more than 20%.
Industry Background
The pact follows a long-running row between the pharmaceutical industry and the UK government over drug pricing and NHS adoption.
These tensions were intensified by claims that US customers were charged several times more for the equivalent treatments than patients in the UK and Europe.
In recent months, several significant pharmaceutical investments in the UK have been delayed or abandoned, while major expansions have been directed toward American operations.
The Science Minister acknowledged that the NHS had to increase expenditure on treatments, noting that its expenditure on drugs had declined as a proportion of its resources over the last ten years.
